Status:
TERMINATED
Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery
Lead Sponsor:
Nova Scotia Health Authority
Conditions:
Cataract
Phacoemulsification
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose is to determine if an intracameral solution of 0.2% tropicamide and 2% phenylephrine can dilate the pupil for cataract surgery as well as pre-operative topical 1% tropicamide and 5% phenyl...
Eligibility Criteria
Inclusion
- Ability to give consent
- Greater than 18 years of age
- Planned clear cornea cataract extraction and placement of foldable posterior chamber intraocular lens
- No secondary procedure planned (i.e. trabeculectomy, keratectomy, corneal transplant, vitreo-retinal procedure etc.)
- Systemic condition capable of undergoing topical anesthesia
- No previous intraocular surgery
- Pseudoexfoliation syndrome (PXF) for group 1
- No Pseudoexfoliation syndrome for group 2
Exclusion
- Not fulfilling inclusion criteria
- Any iris pathology including but not limited to posterior synechia, iridocorneal endothelial syndrome, corectopia, traumatic mydriasis, Horner's syndrome, Adie's pupil, cyclodialysis, iridodialysis
- Previous or concurrent use of Flomax® or similar alpha-antagonist medication
- Corneal pathology affecting pupil magnification or measurement (keratoconus, peripheral thinning, sclerocornea, scarring)
- Uncontrolled Hypertension (greater than 170/90 on pre-operative assessment on day of surgery as measured by automated DATEX monitor)
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00690222
Start Date
March 1 2008
End Date
June 1 2012
Last Update
March 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital District Health Authority
Halifax, Nova Scotia, Canada, B3H 2Y9